Related Experiment Video
Updated: Jan 23, 2026

Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions
Published on: June 28, 2018
SSR2 Promotes Sorafenib Resistance Via Interacting with GPX4 to Inhibit Ferroptosis
Zebing Song1, Mengdan Zhou1, Xiaodong Song1
1Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Guangzhou Medical University. Guangzhou 510000, P.R. China.
Aim & Objectives:
Sorafenib is a first-line drug for hepatocellular carcinoma (HCC). Understanding the regulatory mechanisms of sorafenib resistance is critical to inhibit sorafenib resistance and develop novel therapeutic strategies. Here, we aimed to study the role of SSR2 (signal sequence receptor subunit 2) in sorafenib resistance of HCC.
Methods:
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, colony formation assay, and cell viability assay were used to determine the role of SSR2 in sorafenib resistance of HCC. Co-immunoprecipitation (CoIP) was used to determine the interacting protein of SSR2.
Results:
We found SSR2 was upregulated in sorafenib-resistant HCC tissues. In addition, in HCC patients, SSR2 was associated with both poor response to sorafenib and poor clinical outcomes. Functional assay showed that SSR2 promoted sorafenib resistance in HCC cells. Mechanistically, SSR2 suppressed ferroptosis. Further analysis showed that SSR2 interacted with ferroptosis master regulator glutathione peroxidase 4 (GPX4) and increased the catalytic activity of GPX4, leading to inhibition of ferroptosis. Induction of ferroptosis could reverse the promotion effect of SSR2 overexpression on sorafenib resistance.
Discussion:
SRR2 plays a critical role in sorafenib resistance generation. However, the detailed mechanism of SRR2 increasing the catalytic activity of GPX4 will be further studied.
Conclusions:
In summary, we reveal that SSR2 enhances sorafenib resistance of HCC via interacting with GPX4 and inhibiting ferroptosis, providing a potential target for HCC treatment. The molecular mechanism of GPX4-SSR2 interaction in ferroptosis will be further studied.
Insights
Signal sequence receptor subunit 2 (SSR2) promotes sorafenib resistance in hepatocellular carcinoma (HCC) by inhibiting ferroptosis. Targeting SSR2 may offer a new therapeutic strategy for HCC patients resistant to sorafenib.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Sorafenib is a key first-line treatment for hepatocellular carcinoma (HCC).
- Understanding mechanisms of sorafenib resistance is crucial for improving HCC treatment outcomes.
- Signal sequence receptor subunit 2 (SSR2) has emerged as a potential factor in cancer progression.
Purpose of the Study:
- To investigate the role of SSR2 in sorafenib resistance in HCC.
- To elucidate the molecular mechanisms underlying SSR2-mediated sorafenib resistance.
Main Methods:
- Cell viability assays (MTT, colony formation) to assess SSR2's impact on sorafenib resistance.
- Co-immunoprecipitation (CoIP) to identify SSR2 interacting proteins.
- Functional assays to explore SSR2's effect on ferroptosis and its interaction with GPX4.
Main Results:
- SSR2 was found to be upregulated in sorafenib-resistant HCC tissues and associated with poor clinical outcomes.
- SSR2 overexpression promoted sorafenib resistance in HCC cells by suppressing ferroptosis.
- SSR2 was shown to interact with glutathione peroxidase 4 (GPX4), enhancing its activity and inhibiting ferroptosis.
Conclusions:
- SSR2 plays a significant role in the development of sorafenib resistance in HCC.
- Targeting the SSR2-GPX4 interaction and its effect on ferroptosis presents a potential therapeutic strategy for overcoming sorafenib resistance in HCC.
Related Concept Videos
The Eukaryotic Promoter Region
The Eukaryotic Promoter Region
Feedback Inhibition
Resistivity
Resistance
Enzyme Inhibition

